The ENTA/ABBV collaboration was in the slow lane until it became clear that all-oral HCV regimens would actually work.
Other HCV companies were advancing their compounds in combination with interferon under the guidance of the FDA Pre-2010. At least I was under the impression this was the case. I'm not sure how ABT-450 made it so far, so fast, without "paying its dues" in interferon-based testing.
Market Data 
Markets 
AI
